A cost-utility analysis of an NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected Quality-of-life scores in an economic model of treatment of ovarian cancer

PURPOSE: To estimate quality-of-life (QOL)-adjusted cost-utility with addition of bevacizumab (B) to intravenous paclitaxel/carboplatin (PC) for primary treatment of advanced-stage epithelial ovarian cancer. METHODS: A modified Markov state transition model of 3 regimens evaluated in GOG 218 (PC, PC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Cohn, David E, Barnett, Jason C, Wenzel, Lari, Monk, Bradley J, Burger, Robert A, Straughn, J Michael, Myers, Evan R, Havrilesky, Laura J
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4512835/
https://ncbi.nlm.nih.gov/pubmed/25449568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2014.10.020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados